Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool

Table 2 NUTRIC candidate variables by 28-day mortality status

	Non-survivors (n= 138)	Survivors (n= 460)	P values
Age	71.7 (60.8 to 77.2)	61.7 (49.7 to 71.5)	< 0.001
Baseline APACHE II score	26.0 (21.0 to 31.0)	20.0 (15.0 to 25.0)	< 0.001
Baseline SOFA	9.0 (6.0 to 11.0)	6.0 (4.0 to 8.5)	< 0.001
# of days in hospital prior to ICU admission	0.9 (0.1 to 4.5)	0.3 (0.0 to 2.2)	< 0.001
Baseline BMI	26.0 (22.6 to 29.9)	26.8 (23.4 to 31.5)	0.13
BMI			0.66
< 20	6 (4.3%)	25 (5.4%)
≥20	122 (88.4%)	414 (90.0%)
# of co-morbidities at baseline	3.0 (2.0 to 4.0)	3.0 (1.0 to 4.0)	< 0.001
Co-morbidity			< 0.001
Patients with 0-1 co-morbidity	20 (14.5%)	140 (30.5%)
Patients with 2 or more co-morbidities	118 (85.5%)	319 (69.5%)
C-reactive protein^¶	135.0 (73.0 to 214.0)	108.0 (59.0 to 192.0)	0.07
Procalcitonin^¶	4.1 (1.2 to 21.3)	1.0 (0.3 to 5.1)	< 0.001
Interleukin-6^¶	158.4 (39.2 to 1034.4)	72.0 (30.2 to 189.9)	< 0.001
171 patients had data of recent oral intake and weight loss
	Non-survivors by day 28 ( n = 32)	Survivors by day 28 ( n = 139)	P values
% Oral intake in the week prior to enrolment	4.0 (1.0 to 70.0)	50.0 (1.0 to 100.0)	0.10
% of weight loss in the last three months	0.0 (0.0 to 2.5)	0.0 (0.0 to 0.0)	0.06

APACHE II, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; SOFA, Sequential Organ Failure Assessment.
Values are median (q1 to q3) or n (%).
^¶ Baseline refers to the first available data

ISSN: 1364-8535